Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
Jon Weston
Advertisement
Jon Weston is the president and CEO of PhotonPharma.
Articles by Jon Weston
Advertisement
Latest Updated Articles
Advertisement
Advertisement